Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA review of drug names

This article was originally published in The Tan Sheet

Executive Summary

Drug Safety & Risk Management Advisory Committee will convene Dec. 4 to "discuss current screening methods to assess sound alike and look alike proprietary drug names, in order to reduce the incidence of medication errors." Meeting, previously scheduled for Sept. 18-19, was postponed for weather-related reasons. Session will follow-up on topics explored at a June meeting co-sponsored by FDA, PhRMA and the Institute for Safe Medication Practices (1"The Tan Sheet July 7, 2003, p. 12). Panel will meet at the Holiday Inn in Gaithersburg, from 8 am to 5 pm...

You may also be interested in...



Drug Names Tentatively Accepted As Trademarks Could Be Placed On Internet

FDA is thinking of making tentatively accepted drug trade names viewable on the Internet

Market Intel: Minimally Invasive Procedures Gaining Traction In BPH Treatment Market

Less-invasive technologies to treat benign prostatic hyperplasia are fast becoming viable alternatives to medication and surgery. Landmark studies of newer techniques have led the American Urological Association to update its guidelines.

Innovo Incontinence Device Goes OTC In US, Labeled To Be Worn For 30 Minutes

Atlantic Therapeutics estimates that one in three women are incontinent, but 60% don’t ask their health care providers about treatment, a statistic that supports offering Innovo OTC less than two years after it launched Rx in the US.

Topics

UsernamePublicRestriction

Register

PS096215

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel